Arcadia Capital, the premier strategic advisor and investment bank to leaders in the tech and tech services ecosystem, served as exclusive financial advisor to InformedDNA (“IDNA” or “the Company”), a portfolio company of Truehelm and QHP Capital, in the divestiture of its Genetic Testing Utilization Management (“GTUM”) business unit to Zyter, a subsidiary of Infinite, a global technology company. The transaction marks the Company’s continued investment in and focus on DNAimpact, its category-defining precision health platform, and follows the May 2026 divestiture of IDNA’s Payment Integrity business unit. The GTUM unit partners with health plans to bring clinical rigor to one of the fastest-moving categories of medical spend.
Read the full article: Arcadia Capital Advises InformedDNA on Divestiture of Genetic Testing Utilization Management Business Unit to Zyter //
Source: https://www.businesswire.com/news/home/20260818187524/en/Arcadia-Capital-Advises-InformedDNA-on-Divestiture-of-Genetic-Testing-Utilization-Management-Business-Unit-to-Zyter